Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND

ASSEMBLY BIOSCIENCES, INC.

2023-Q1 EPS reported -$0.37

Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.
Cash, cash equivalents and marketable securities $73.0M as of March 31, 2023, projected to fund ops into Q3 2024.
Nominated first herpesvirus candidate ABI-5366; plans to enter clinic first half 2024; expects additional candidate nomination in 2023.
Evaluating partnering options for core HBV inhibitor portfolio to focus on expanded virology programs.
Multiple abstracts accepted for presentation at EASL 2023 in June for HBV/HDV entry inhibitor and core inhibitor data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: net income $19.0 million, EPS $0.37 per basic and diluted share.

Period: first quarter ended March 31, 2023
Net income: $19.0 million
EPS: $0.37 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $19.0 million, or $0.37 per basic and diluted share, for the three months ended March 31, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-017924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.